He is a past Biology Fellow with the California Institute of Technology, Pasadena. Robert is a board member of Ahram Biosystems (PCR diagnostics) and is a co-founder of Idogen AB (tolerogenic cell therapies): a company listed on the Swedish stock exchange in (IDOGEN:ST).Robert is a past law partner of Edwards Angell Palmer & Dodge (now Locke Lord) in Boston.Robert received a BS from the University of Massachusetts, Amherst (Biochemistry), a PhD from the University of California, Los Angeles (Biochemistry), and a JD in law from Suffolk University, Boston. He was lead or co-lead IP counsel for a broad range of transactions in which total upfront and future milestone payments exceeded USD $1.25B. In 2018, Complement Pharma announced a partnership with Alexion (NASDAQ:ALXN) to co-develop drugs treating neurodegenerative disorders worth a total of EUR 14M.Prior to joining Avexxin AS, Robert was Associate General Counsel at Biogen (NASDAQ:BIIB) where responsibilities included oversight of the company’s early stage hemophilia patent portfolio and strengthening its R&D collaboration pipeline in gene therapy and gene editing projects. Other past executive level positions include CEO of Regenesance BV (now Complement Pharma BV), a company Robert co-founded. He is General Counsel for Avexxin AS: a clinical stage Ventac Partners’ portfolio company developing anti-inflammatory agents. Omaida Velazquez to treat limb ischemia.Robert has over 20 years of experience in executive level management roles. The company is focused on commercializing gene & cell therapies discovered by Dr. He recently spun a company, Ambulero, out of the University of Miami. Buchanan is a partner at Ventac Partners, an investment, company building and consultancy firm. Bob Buchanan, PhD, JD Partner Ventac Partners
0 kommentar(er)
